Fundraising of €0.25 million by Neovacs

Neovacs, a biotechnology company listed on Euronext Growth Paris, announces a €0.25 million fundraising. This transaction, carried out through the issuance of OCEANE-BSA bonds, was underwritten by the European High Growth Opportunities Securitization Fund. The net proceeds of €240,000 will finance the Kinoïde® allergy program and strengthen investments in biomedical projects.

Today's offering could create 4,672,897 new shares. The total offering could result in the creation of 7,476,635 shares. The shares will be sold quickly on the market, potentially putting pressure on the share price. Neovacs warns investors of the risks of dilution and a possible decline in share value.